Acer Therapeutics Reacquires Worldwide Development, Commercialization And Economic Rights To OLPRUVA From Relief Therapeutics, Excluding The Geographical Europe; Relief To Receive $10M And $1.5M Additionally
Portfolio Pulse from Benzinga Newsdesk
Acer Therapeutics has reacquired worldwide development, commercialization, and economic rights to OLPRUVA from Relief Therapeutics, excluding Europe. Relief Therapeutics will receive $10M and an additional $1.5M.
August 30, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acer Therapeutics reacquires rights to OLPRUVA, potentially boosting its product portfolio and future revenues.
The reacquisition of OLPRUVA rights by Acer Therapeutics could potentially enhance its product portfolio and future revenues. This could be seen as a positive development by investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100